Text Size

The Interrelation of the Vasculature, Endothelium, Bone Metabolism and Uremic Toxins in Peritoneal Dialysis (INVEST-PD)

This study has been completed.
Sponsor:
Information provided by:
Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
NCT00433264
First received: February 7, 2007
Last updated: March 4, 2009
Last verified: March 2009
History of Changes
  Purpose

Despite major advances in the treatment of chronic kidney disease, the age and sex matched mortality far exceeds that of the normal population. As in the normal population, the majority of deaths are related to cardiovascular disease. Mounting data point to the lethal synergy between chronic kidney disease and cardiovascular disease. This relation is present from early stages of chronic kidney disease on.

Several uremic toxins have been demonstrated to play an important role in kidney disease related endothelial dysfunction. In peritoneal dialysis patients, data on the relation between uremic toxins, endothelial dysfunction and microparticles are lacking.

The investigators hypothesize that endothelial dysfunction and uremic toxins are interrelated in peritoneal dialysis patients


Condition Intervention Phase
Chronic Kidney Disease
 Procedure: peritoneal dialysis
 Phase 0

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Interrelation of the Vasculature, Endothelium, Bone Metabolism and Uremic Toxins in Peritoneal Dialysis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Universitaire Ziekenhuizen Leuven:

Biospecimen Retention:   Samples With DNA

serum, plasma, DNA


Enrollment: 62
Study Start Date: February 2007
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: peritoneal dialysis
    individualised
    Other Name: individualised
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Tertiary referral center university hospital

Criteria

Inclusion Criteria:

  • age > 18
  • Maintenance peritoneal dialysis

Exclusion Criteria:

  • No informed consent
  • Peritonitis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00433264

Locations
Belgium
Universitaire Ziekenhuizen Leuven
Leuven, Vlaams-Brabant, Belgium, 3000
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Investigators
Principal Investigator: Bjorn Meijers, MD UZ Leuven
Principal Investigator: Kathleen Claes, MD UZ Leuven
Study Director: Pieter Evenepoel, MD, PhD UZ Leuven
  More Information

No publications provided

Responsible Party: Pieter Evenepoel, University Hospitals Leuven
ClinicalTrials.gov Identifier: NCT00433264     History of Changes
Other Study ID Numbers: ML3645
Study First Received: February 7, 2007
Last Updated: March 4, 2009
Health Authority: Belgium: Institutional Review Board

Keywords provided by Universitaire Ziekenhuizen Leuven:
peritoneal dialysis
endothelium
endothelial dysfunction

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency

ClinicalTrials.gov processed this record on May 23, 2013